Merck (MRK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

While Merck reported strong financial results in recent quarters, it faces both upsides and risks in the future. Read why I'm ...

We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors should consider selling the same.

Merck reported adjusted earnings of $1.72 per ... a charge of 23 cents related to M&A deals with LaNova Medicines and Hansoh Pharma. Revenues rose 7% year over year (9% excluding Fx) to $15. ...

China’s DeepSeek shocked the world by delivering unexpected innovation at an unbelievable price. But this disruptive trend ...

Merck & Co., Inc. (NYSE ... The company also secured a $2 billion licensing deal with Chinese drugmaker Hansoh Pharma in December 2024 for an experimental weight loss pill. This strategic move ...

Also, Viking was seen by some as a potential acquisition target for Merck. However, Merck announced in December 2024 it was licensing Hansoh Pharma's obesity drug HS-10535. This move added a new (and ...

Merck is one of the largest pharmaceutical companies ... HS-10535, with China-based Hansoh Pharma. It signed a similar licensing deal with LaNova Medicines for the development of LM-299, a ...

AstraZeneca signed a $1.92 billion deal with China’s CSPC Pharmaceutical Group last year to develop cardiovascular medication, and Merck has a $2 billion agreement with China’s Hansoh ...